CANF Can-Fite Biopharma Ltd
$1.65▼ -4.07%
Healthcare
Other
After hours
$1.63▼ -1.21%
Oct 27, 5:17 PM ET
Volume 77.7K
Avg Volume (10D) 103.0K
Key Metrics & Fundamentals
Market Cap
$5.00M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.60 - 12.40
% vs 50 MA
-30.27%
% vs 200 MA
-49.20%
RSI-14
23.9
MACD Histogram
+0.0000
Beta (1Y vs SPY)
0.73
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
GlobeNewswire · Oct 26, 2026 7:00 AM ET
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
GlobeNewswire · Sep 9, 2026 7:00 AM ET
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
GlobeNewswire · Sep 8, 2026 8:20 AM ET
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
GlobeNewswire · Sep 2, 2026 9:02 AM ET
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
GlobeNewswire · Sep 2, 2026 7:00 AM ET
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
GlobeNewswire · Aug 17, 2026 7:00 AM ET
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
GlobeNewswire · Aug 12, 2026 7:00 AM ET
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
GlobeNewswire · Aug 3, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.